Literature DB >> 33832818

Options for imaging cellular therapeutics in vivo: a multi-stakeholder perspective.

Brooke M Helfer1, Vladimir Ponomarev2, P Stephen Patrick3, Philip J Blower4, Alexandra Feitel5, Gilbert O Fruhwirth4, Shawna Jackman6, Lucilia Pereira Mouriès7, Margriet V D Z Park8, Mangala Srinivas9, Daniel J Stuckey3, Mya S Thu10, Tineke van den Hoorn11, Carla A Herberts11, William D Shingleton12.   

Abstract

Cell-based therapies have been making great advances toward clinical reality. Despite the increase in trial activity, few therapies have successfully navigated late-phase clinical trials and received market authorization. One possible explanation for this is that additional tools and technologies to enable their development have only recently become available. To support the safety evaluation of cell therapies, the Health and Environmental Sciences Institute Cell Therapy-Tracking, Circulation and Safety Committee, a multisector collaborative committee, polled the attendees of the 2017 International Society for Cell & Gene Therapy conference in London, UK, to understand the gaps and needs that cell therapy developers have encountered regarding safety evaluations in vivo. The goal of the survey was to collect information to inform stakeholders of areas of interest that can help ensure the safe use of cellular therapeutics in the clinic. This review is a response to the cellular imaging interests of those respondents. The authors offer a brief overview of available technologies and then highlight the areas of interest from the survey by describing how imaging technologies can meet those needs. The areas of interest include imaging of cells over time, sensitivity of imaging modalities, ability to quantify cells, imaging cellular survival and differentiation and safety concerns around adding imaging agents to cellular therapy protocols. The Health and Environmental Sciences Institute Cell Therapy-Tracking, Circulation and Safety Committee believes that the ability to understand therapeutic cell fate is vital for determining and understanding cell therapy efficacy and safety and offers this review to aid in those needs. An aim of this article is to share the available imaging technologies with the cell therapy community to demonstrate how these technologies can accomplish unmet needs throughout the translational process and strengthen the understanding of cellular therapeutics.
Copyright © 2021 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  biodistribution; cell therapy; fate; in vivo tracking; non-invasive; safety

Year:  2021        PMID: 33832818      PMCID: PMC9344904          DOI: 10.1016/j.jcyt.2021.02.005

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   6.196


  175 in total

1.  In vivo tracking of stem cells for clinical trials in cardiovascular disease.

Authors:  John V Frangioni; Roger J Hajjar
Journal:  Circulation       Date:  2004-11-23       Impact factor: 29.690

2.  Tracking neural stem cells in patients with brain trauma.

Authors:  Jianhong Zhu; Liangfu Zhou; FengGe XingWu
Journal:  N Engl J Med       Date:  2006-11-30       Impact factor: 91.245

3.  Dual-modality monitoring of targeted intraarterial delivery of mesenchymal stem cells after transient ischemia.

Authors:  Piotr Walczak; Jian Zhang; Assaf A Gilad; Dorota A Kedziorek; Jesus Ruiz-Cabello; Randell G Young; Mark F Pittenger; Peter C M van Zijl; Judy Huang; Jeff W M Bulte
Journal:  Stroke       Date:  2008-03-06       Impact factor: 7.914

4.  Preclinical safety evaluation of 18F-FHBG: a PET reporter probe for imaging herpes simplex virus type 1 thymidine kinase (HSV1-tk) or mutant HSV1-sr39tk's expression.

Authors:  Shahriar S Yaghoubi; Marcelo A Couto; Chang-Cheng Chen; Lathasree Polavaram; Guanggen Cui; Luyi Sen; Sanjiv S Gambhir
Journal:  J Nucl Med       Date:  2006-04       Impact factor: 10.057

5.  Clinically applicable magnetic-labeling of natural killer cells for MRI of transcatheter delivery to liver tumors: preclinical validation for clinical translation.

Authors:  Kangan Li; Andrew C Gordon; Linfeng Zheng; Weiguo Li; Yang Guo; Jing Sun; Guixiang Zhang; Guohong Han; Andrew C Larson; Zhuoli Zhang
Journal:  Nanomedicine (Lond)       Date:  2015       Impact factor: 5.307

6.  Superparamagnetic iron oxide nanoparticles labeling of bone marrow stromal (mesenchymal) cells does not affect their "stemness".

Authors:  Arun Balakumaran; Edyta Pawelczyk; Jiaqiang Ren; Brian Sworder; Aneeka Chaudhry; Marianna Sabatino; David Stroncek; Joseph A Frank; Pamela G Robey
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

7.  In vivo trafficking and targeted delivery of magnetically labeled stem cells.

Authors:  Ali S Arbab; Elaine K Jordan; Lindsey B Wilson; Gene T Yocum; Bobbi K Lewis; Joseph A Frank
Journal:  Hum Gene Ther       Date:  2004-04       Impact factor: 5.695

8.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

9.  Self-assembling nanocomplexes by combining ferumoxytol, heparin and protamine for cell tracking by magnetic resonance imaging.

Authors:  Mya S Thu; L Henry Bryant; Tiziana Coppola; E Kay Jordan; Matthew D Budde; Bobbi K Lewis; Aneeka Chaudhry; Jiaqiang Ren; Nadimpalli Ravi S Varma; Ali S Arbab; Joseph A Frank
Journal:  Nat Med       Date:  2012-02-26       Impact factor: 53.440

10.  MRI-guided interventional natural killer cell delivery for liver tumor treatment.

Authors:  Zhanliang Su; Xifu Wang; Linfeng Zheng; Tianchu Lyu; Matteo Figini; Bin Wang; Daniel Procissi; Junjie Shangguan; Chong Sun; Liang Pan; Lei Qin; Bin Zhang; Yury Velichko; Riad Salem; Vahid Yaghmai; Andrew C Larson; Zhuoli Zhang
Journal:  Cancer Med       Date:  2018-03-30       Impact factor: 4.452

View more
  1 in total

1.  Optimization of Multimodal Nanoparticles Internalization Process in Mesenchymal Stem Cells for Cell Therapy Studies.

Authors:  Mariana P Nucci; Javier B Mamani; Fernando A Oliveira; Igor S Filgueiras; Arielly H Alves; Matheus H Theinel; Luiz D Rodrigues; Luciana Marti; Lionel F Gamarra
Journal:  Pharmaceutics       Date:  2022-06-12       Impact factor: 6.525

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.